Enliven Therapeutics (NASDAQ:ELVN) Sets New 52-Week Low on Insider Selling

Enliven Therapeutics, Inc. (NASDAQ:ELVN)’s share price hit a new 52-week low on Wednesday after an insider sold shares in the company. The stock traded as low as $17.82 and last traded at $18.94, with a volume of 157800 shares changing hands. The stock had previously closed at $18.65.

Specifically, CFO Benjamin Hohl sold 3,250 shares of the company’s stock in a transaction on Monday, April 28th. The shares were sold at an average price of $18.69, for a total value of $60,742.50. Following the transaction, the chief financial officer now directly owns 23,000 shares of the company’s stock, valued at approximately $429,870. This represents a 12.38 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Wall Street Analyst Weigh In

Separately, HC Wainwright boosted their target price on Enliven Therapeutics from $37.00 to $39.00 and gave the company a “buy” rating in a research note on Friday, March 21st.

Enliven Therapeutics Price Performance

The stock has a market capitalization of $972.73 million, a price-to-earnings ratio of -10.45 and a beta of 1.03. The stock’s 50 day simple moving average is $19.16 and its 200-day simple moving average is $22.47.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings data on Thursday, March 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.07. The business had revenue of $0.03 million during the quarter. As a group, equities research analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Institutional Trading of Enliven Therapeutics

Several large investors have recently made changes to their positions in the stock. Tower Research Capital LLC TRC raised its stake in shares of Enliven Therapeutics by 230.2% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company’s stock valued at $36,000 after acquiring an additional 1,114 shares in the last quarter. GAMMA Investing LLC grew its holdings in Enliven Therapeutics by 3,058.1% during the first quarter. GAMMA Investing LLC now owns 2,716 shares of the company’s stock valued at $53,000 after purchasing an additional 2,630 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of Enliven Therapeutics in the fourth quarter valued at approximately $97,000. BNP Paribas Financial Markets acquired a new stake in shares of Enliven Therapeutics in the fourth quarter worth $112,000. Finally, ExodusPoint Capital Management LP bought a new stake in shares of Enliven Therapeutics during the 4th quarter worth $200,000. Institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.